Skip to main
NMRA

NMRA Stock Forecast & Price Target

NMRA Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Neumora Therapeutics has strategically developed a robust pipeline that includes seven clinical and preclinical programs targeting novel mechanisms for a variety of neuropsychiatric and neurodegenerative disorders, which positions the company favorably in addressing significant unmet medical needs. Financial projections indicate potential US sales of $250 million in 2030 and $950 million by 2035, aligning with consensus estimates and demonstrating strong commercial potential for its lead asset, navacaprant, which is expected to achieve US sales of $750 million by 2028 and $3 billion at peak. Recent updates highlight the promising efficacy of NMRA-511 in Alzheimer's-related agitation and improved trial demographics, reinforcing optimism about its competitive advantage and strong market positioning in the treatment landscape.

Bears say

Neumora Therapeutics Inc. reported a significant net loss of $59.5 million in the fourth quarter of 2025, with research and development expenses totaling $44.7 million, highlighting ongoing financial strain as the company continues to advance its clinical programs. The negative outlook is further exacerbated by investor concerns regarding adverse event findings in the NMRA-215 program, raising doubts about its viability and future prospects. Additionally, the company's dependence on external financing to support its research initiatives until it becomes cash flow positive introduces substantial risks, including the potential for setbacks in clinical trials and increased market competition.

NMRA has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neumora Therapeutics Inc (NMRA) Forecast

Analysts have given NMRA a Buy based on their latest research and market trends.

According to 6 analysts, NMRA has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neumora Therapeutics Inc (NMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.